Response to therapy (N = 46)
| Response . | All . | Treated with RUX and AZA (n = 41) . | Patients with splenomegaly* (n = 34) . | Time to response† . | ||||
|---|---|---|---|---|---|---|---|---|
| No. . | %‡ . | No. . | %‡ . | No. . | %‡ . | Months . | Range . | |
| Individual responses§ | ||||||||
| PR overall‖ | 2 | 4 | 2 | 5 | 2 | 6 | 14.5 | 10-19 |
| PR including clinical improvement for spleen and hemoglobin | 1 | 2 | 1 | 2 | 1 | 3 | 19 | |
| PR including clinical improvement for TSS, spleen, and hemoglobin | 1 | 2 | 1 | 2 | 1 | 3 | 10 | |
| Clinical improvement overall | 31 | 67 | 31 | 76 | 21 | 62 | 4 | 0.3-15 |
| Clinical improvement for TSS and spleen | 9 | 20 | 9 | 22 | 9 | 26 | 5 | |
| Clinical improvement for spleen; cytogenetic CR | 2 | 4 | 2 | 5 | 2 | 6 | 5.4 | |
| Clinical improvement for TSS; cytogenetic CR | 1 | 2 | 1 | 2 | 0 | 5.5 | ||
| Clinical improvement for TSS and hemoglobin | 2 | 4 | 2 | 5 | 1 | 3 | 4 | 0.7-15 |
| Clinical improvement for TSS only | 11 | 24 | 11 | 27 | 3 | 9 | 1.8 | 0.5-10 |
| Clinical improvement for spleen only | 6 | 13 | 6 | 15 | 8 | 24 | 1.5 | 0.3-12 |
| NR/SD | 11 | 24 | 8 | 20 | 9 | 26 | — | |
| PD (AML) | 2 | 4 | 2 | 5 | 2 | 6 | — | |
| Response types¶ | ||||||||
| Clinical improvement for spleen | 21 | 47 | 19 | 46 | 21 | 62 | 1.8 | 0.5-18 |
| Clinical improvement for TSS | 22 | 48 | 16 | 54 | 16 | 47 | 2 | 0.7-16 |
| Clinical improvement for hemoglobin | 4 | 9 | 3 | 7 | 3 | 9 | 5.8 | 1.1-15 |
| Clinical improvement for cytogenetics | 3 | 7 | 3 | 7 | 3 | 9 | 6 | 6-12 |
| Response . | All . | Treated with RUX and AZA (n = 41) . | Patients with splenomegaly* (n = 34) . | Time to response† . | ||||
|---|---|---|---|---|---|---|---|---|
| No. . | %‡ . | No. . | %‡ . | No. . | %‡ . | Months . | Range . | |
| Individual responses§ | ||||||||
| PR overall‖ | 2 | 4 | 2 | 5 | 2 | 6 | 14.5 | 10-19 |
| PR including clinical improvement for spleen and hemoglobin | 1 | 2 | 1 | 2 | 1 | 3 | 19 | |
| PR including clinical improvement for TSS, spleen, and hemoglobin | 1 | 2 | 1 | 2 | 1 | 3 | 10 | |
| Clinical improvement overall | 31 | 67 | 31 | 76 | 21 | 62 | 4 | 0.3-15 |
| Clinical improvement for TSS and spleen | 9 | 20 | 9 | 22 | 9 | 26 | 5 | |
| Clinical improvement for spleen; cytogenetic CR | 2 | 4 | 2 | 5 | 2 | 6 | 5.4 | |
| Clinical improvement for TSS; cytogenetic CR | 1 | 2 | 1 | 2 | 0 | 5.5 | ||
| Clinical improvement for TSS and hemoglobin | 2 | 4 | 2 | 5 | 1 | 3 | 4 | 0.7-15 |
| Clinical improvement for TSS only | 11 | 24 | 11 | 27 | 3 | 9 | 1.8 | 0.5-10 |
| Clinical improvement for spleen only | 6 | 13 | 6 | 15 | 8 | 24 | 1.5 | 0.3-12 |
| NR/SD | 11 | 24 | 8 | 20 | 9 | 26 | — | |
| PD (AML) | 2 | 4 | 2 | 5 | 2 | 6 | — | |
| Response types¶ | ||||||||
| Clinical improvement for spleen | 21 | 47 | 19 | 46 | 21 | 62 | 1.8 | 0.5-18 |
| Clinical improvement for TSS | 22 | 48 | 16 | 54 | 16 | 47 | 2 | 0.7-16 |
| Clinical improvement for hemoglobin | 4 | 9 | 3 | 7 | 3 | 9 | 5.8 | 1.1-15 |
| Clinical improvement for cytogenetics | 3 | 7 | 3 | 7 | 3 | 9 | 6 | 6-12 |
NR, no response; PD, progressive disease; PR, partial remission; SD, stable disease.
Splenomegaly ≥5 cm below costal margin.
In case of combined response, time to response is based on time to the longest response. Time to response is calculated as median for 2 or more responders, and as the best time to response for single responder.
Percentages are calculated from all patients at risk.
Individual best response per IWG-MRT criteria.
Both PRs happened after AZA was added with achievement of clinical improvement in spleen length (entire spleen response after AZA [n = 1]; continuing improvement in spleen length [n = 1]).
Summarizes overall frequency of each type of response.